P2X3 receptors desensitize within 100 ms of channel activation, yet recovery from desensitization requires several minutes. The molecular basis for this slow rate of recovery is unknown. We designed experiments to test the hypothesis that this slow recovery is attributable to the high affinity (< 1 nM) of desensitized P2X3 receptors for agonist. We found that agonist binding to the desensitized state provided a mechanism for potent inhibition of P2X3 current. Sustained applications of 0.5 nM ATP inhibited > 50% of current to repetitive applications of P2X3 agonist. Inhibition occurred at 1000-fold lower agonist concentrations than required for channel activation and showed strong use dependence. No inhibition occurred without previous activation and desensitization. Our data are consistent with a model whereby inhibition of P2X3 by nanomolar [agonist] occurs by the rebinding of agonist to desensitized channels before recovery from desensitization. For several ATP analogs, the concentration required to inhibit P2X3 current inversely correlated with the rate of recovery from desensitization. This indicates that the affinity of the desensitized state and recovery rate primarily depend on the rate of agonist unbinding. Consistent with this hypothesis, unbinding of [32P]ATP from desensitized P2X3 receptors mirrored the rate of recovery from desensitization. As expected, disruption of agonist binding by site-directed mutagenesis increased the IC50 for inhibition and increased the rate of recovery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6725291 | PMC |
http://dx.doi.org/10.1523/JNEUROSCI.5189-04.2005 | DOI Listing |
J Biol Chem
December 2024
Department of Biological Sciences, Purdue University, West Lafayette, IN-47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN-47907, USA. Electronic address:
ATP-activated P2X3 receptors play a pivotal role in chronic cough, affecting more than 10% of the population. Despite the challenges posed by the highly conserved structure of P2X receptors, efforts to develop selective drugs targeting P2X3 have led to the development of camlipixant, a potent, selective P2X3 antagonist. However, the mechanisms of receptor desensitization, ion permeation, and structural basis of camlipixant binding to P2X3 remain unclear.
View Article and Find Full Text PDFJ Formos Med Assoc
December 2024
Department of Life Science, College of Science, National Taiwan Normal University, 162, Section 1, Heping E. Rd., Taipei, 106, Taiwan. Electronic address:
Background/purpose: The mechanism for long-term hypoxia/ischemia induced bladder underactivity is uncertain. It requires an effectively therapeutic treatment. Therefore, we determined the pathophysiologic mechanisms of long-term bilateral partial iliac arterial occlusion (BPAO)-induced bladder underactivity and explored the therapeutic potential of adipose-derived stem cells (ADSCs) and ADSC-derived microvesicles (MVs) on BPAO-induced bladder dysfunction.
View Article and Find Full Text PDFPurinergic Signal
November 2024
Department of Physiology, Michigan State University, 567 Wilson Road, East Lansing, MI, 48824, USA.
Purines are important mediators of intercellular communication in the enteric nervous system (ENS) that participate in physiological gut functions and disease. Purinergic transmission is prominent in mechanisms of crosstalk between enteric neurons and glia where enteric glia exhibit high responsiveness to adenosine diphosphate (ADP) through P2Y receptors and neurons to adenosine triphosphate (ATP) through P2X receptors. Despite functional data suggesting that enteric glia are the primary site of P2Y expression in the ENS, gene sequencing suggests that P2Y expression is more enriched in neurons than glia.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
November 2024
Centre for Human and Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Chronic cough remains a significant clinical challenge, affecting approximately 10% of the population and leading to significant impairment in psychological, social, and physical quality of life. In recent years, efforts have intensified to elucidate the mechanisms underlying chronic cough and to focus on investigating and treating refractory chronic cough (RCC). A "treatable trait" approach, which focuses on identifying and addressing the specific associated causes of chronic cough, has gained traction.
View Article and Find Full Text PDFFront Cell Neurosci
October 2024
Division of Oral Biology, Faculty of Dentistry, Khon Kaen University, Khon Kaen, Thailand.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!